Payment overview · 2025
General Payments
$163.64
9 reported records · 7 companies
Healthcare provider profile · identity verified
April Turner, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1629043864
Verified facts
What the public records show
CMS Open Payments records show April Turner, MD received $163.64 in general payments during 2025 across 9 reported records.
Sumitomo Pharma America, Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.82 | 20.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.22 | 19.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.40 | 15.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.25 | 14.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.74 | 12.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.19 | 9.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.02 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $163.64 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 663 | 330 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 119 |
| Lisinopril | Lisinopril | 248 | 125 |
| Losartan Potassium | Losartan Potassium | 197 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 108 |
| Ezetimibe | Ezetimibe | 194 | 106 |
| Prednisone | Prednisone | 177 | 146 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 95 |
| Gabapentin | Gabapentin | 159 | 88 |
| Methylprednisolone | Methylprednisolone | 159 | 137 |
| Alprazolam | Alprazolam | 152 | 50 |
| Metformin Hcl Er | Metformin Hcl | 148 | 77 |
| Omeprazole | Omeprazole | 148 | 82 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 108 |
| Trazodone Hcl | Trazodone Hcl | 125 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 64 |
| Azithromycin | Azithromycin | 119 | 104 |
| Fenofibrate | Fenofibrate | 118 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 65 |
| Montelukast Sodium | Montelukast Sodium | 116 | 68 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 105 | 88 |
| Eliquis | Apixaban | 101 | 54 |
| Meloxicam | Meloxicam | 97 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 82 |
| Furosemide | Furosemide | 84 | 53 |
| Metformin Hcl | Metformin Hcl | 79 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 49 |
| Fluconazole | Fluconazole | 75 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 43 |
| Potassium Chloride | Potassium Chloride | 74 | 40 |
| Simvastatin | Simvastatin | 74 | 33 |
| Cephalexin | Cephalexin | 72 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 23 |
| Clonazepam | Clonazepam | 64 | 14 |
| Sertraline Hcl | Sertraline Hcl | 63 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 60 | 48 |
| Alendronate Sodium | Alendronate Sodium | 59 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 31 |
| Invokana | Canagliflozin | 54 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 38 |
| Carvedilol | Carvedilol | 45 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 21 |
| Lorazepam | Lorazepam | 41 | 14 |
| Bupropion Xl | Bupropion Hcl | 40 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 11 |
| Famotidine | Famotidine | 39 | 23 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 39 | 22 |
| Buspirone Hcl | Buspirone Hcl | 37 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 20 |
| Finasteride | Finasteride | 36 | 21 |
| Allopurinol | Allopurinol | 34 | 19 |
| Celecoxib | Celecoxib | 34 | 25 |
| Cefdinir | Cefdinir | 33 | 32 |
| Memantine Hcl | Memantine Hcl | 30 | 12 |
| Tramadol Hcl | Tramadol Hcl | 29 | 15 |
| Tresiba | Insulin Degludec | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 19 |
| Mupirocin | Mupirocin | 27 | 24 |
| Estradiol | Estradiol | 25 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 20 |
| Spironolactone | Spironolactone | 25 | 13 |
| Atenolol | Atenolol | 24 | 16 |
| Clonidine Hcl | Clonidine Hcl | 24 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | 13 |
| Diazepam | Diazepam | 23 | 14 |
| Methocarbamol | Methocarbamol | 23 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | 12 |
| Temazepam | Temazepam | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 14 |
| Warfarin Sodium | Warfarin Sodium | 23 | 11 |
| Mirtazapine | Mirtazapine | 22 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 15 |
| Glipizide | Glipizide | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 17 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | 11 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | 13 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | 13 |
| Methimazole | Methimazole | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $163.64 · 9 records | Sumitomo Pharma America, Inc. | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, GEMTESA, JARDIANCE, NURTEC ODT, Ozempic, Rybelsus, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error